IFCT-1302

Publications:
  • Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK) : a French nationwide cohort retrospective study
    •
    Synopsis: IFCT-1302_CLINALK_résumé.pdf